Oppenheimer Raises Numbers on Tangoe (TNGO); ttMobiles Acquisition Accretive
TNGO Hot Sheet
Rating Summary:7 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Oppenheimer maintains an 'Outperform' on Tangoe (NASDAQ: TNGO) price target raised $1 to $21.
Analyst, Brad Reback, said, "We view this as yet another solid acquisition for Tangoe as it expands its European footprint, adds complementary mobile TEM technology to its growing portfolio, and provides plenty of up/cross-sell opportunities to legacy customers. Further, we continue to believe Tangoe can deliver at least 15-20% organic recurring revenue growth through a variety of drivers for the foreseeable future."
"We now expect FY12E EPS/rev. of $0.42/$143.1M and FY13E of $0.61/$169.2M from $0.41/$138.6M and $0.59/$164.2M, respectively."
For an analyst ratings summary and ratings history on Tangoe click here. For more ratings news on Tangoe click here.
Shares of Tangoe closed at $17.74 yesterday, with a 52 week range of $8.01-$18.48.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
Analyst, Brad Reback, said, "We view this as yet another solid acquisition for Tangoe as it expands its European footprint, adds complementary mobile TEM technology to its growing portfolio, and provides plenty of up/cross-sell opportunities to legacy customers. Further, we continue to believe Tangoe can deliver at least 15-20% organic recurring revenue growth through a variety of drivers for the foreseeable future."
"We now expect FY12E EPS/rev. of $0.42/$143.1M and FY13E of $0.61/$169.2M from $0.41/$138.6M and $0.59/$164.2M, respectively."
For an analyst ratings summary and ratings history on Tangoe click here. For more ratings news on Tangoe click here.
Shares of Tangoe closed at $17.74 yesterday, with a 52 week range of $8.01-$18.48.
Discover Wall Street's best ratings calls with the pros - Upgrade to Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
- Barclays Maintains an 'Equalweight' on Teva Pharma (TEVA); Adjusting Estimates After Business Update
- Barclays Cuts Estimates and Price Target on ADP (ADP); Mixed Data From Investor Day
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT Change, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
